| SEC Form 4 |  |
|------------|--|
|------------|--|

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person\* (Check all applicable) Inozyme Pharma, Inc. [ INZY ] Mathers Edward T Director 10% Owner 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify 06/18/2024 below) below) (Last) (First) (Middle) 104 5TH AVE 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) 1 Form filed by One Reporting Person (Street) Form filed by More than One Reporting NEW YORK 10011 NY Person Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Code (Inst |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |       | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|---------------------------------|--|---|------------|---|---|---------------|-------|---|---|---|
|                                 |  |   | Code       | v | Amount  | (A) or<br>(D) | Price | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                |   | (Instr. 4)  |

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | 5. Numb<br>of<br>Derivati<br>Securiti<br>Acquire<br>(A) or<br>Dispose<br>of (D) (II<br>3, 4 and | ive<br>ies<br>ed<br>ed<br>nstr. | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | of Securities   |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|------------------------------|---|---|---------------------------------|--|--------------------|-----------------|--|---|--|--|--|
|   |   |  |   | Code                         | v | (A)   | (D)                             | Date<br>Exercisable  | Expiration<br>Date | Title           | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(right to<br>buy)                | \$4.4   | 06/18/2024                                 |   | A                            |   | 28,000  |                                 | (1)  | 06/17/2034         | Common<br>Stock | 28,000                                 | \$0   | 28,000   | D  |  |

Explanation of Responses:

1. The option was granted on June 18, 2024. The shares underlying the option are scheduled to vest as to 100% of the shares on June 18, 2025, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.

| /s/ Zachary<br>in-fact | Bambach, | attorney- | 06/20/2024 |
|------------------------|----------|-----------|------------|
|                        |          |           |            |

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the "SEC"), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-infact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

<u>/s/ Peter J. Barris</u> Peter J. Barris

<u>/s/ Forest Baskett</u> Forest Baskett

/s/ Ali Behbahani Ali Behbahani

/s/ Ronald D. Bernal Ronald D. Bernal

/s/ Ann Bordetsky Ann Bordetsky

<u>/s/ Carmen Chang</u> Carmen Chang

<u>/s/ Philip Chopin</u> Philip Chopin

<u>/s/ Anthony A. Florence, Jr.</u> Anthony A. Florence, Jr.

<u>/s/ Jonathan Golden</u> Jonathan Golden

/s/ Scott Gottlieb

Scott Gottlieb

<u>/s/ Mark Hawkins</u> Mark Hawkins

<u>/s/ Jeffrey R. Immelt</u> Jeffrey R. Immelt

/s/ Aaron Jacobson Aaron Jacobson

/s/ Patrick J. Kerins Patrick J. Kerins

<u>/s/ Hilarie Koplow-McAdams</u> Hilarie Koplow-McAdams

<u>/s/ Vanessa Larco</u> Vanessa Larco

/s/ Julio C. Lopez Julio C. Lopez

<u>/s/ Tiffany Le</u> Tiffany Le

<u>/s/ Mohamad H. Makhzoumi</u> Mohamad H. Makhzoumi

/s/ Edward T. Mathers Edward T. Mathers

<u>/s/ Gregory Papadopoulos</u> Gregory Papadopoulos

<u>/s/ Kavita Patel</u> Kavita Patel

/s/ Scott D. Sandell Scott D. Sandell

/s/ A. Brooke Seawell A. Brooke Seawell

/s/ Peter Sonsini Peter Sonsini

<u>/s/ Melissa Taunton</u> Melissa Taunton

/s/ Paul E. Walker



Paul E. Walker

<u>/s/ Rick Yang</u> Rick Yang